Overview
Pharmacogenomics holds both promise and peril for the pharmaceutical industry.
The advantages have been widely touted: improving the quality of drug targets
and compounds advanced into development, streamlining clinical trials, protection
of market share by reducing adverse events, and laying the foundation of personalized
medicine - "the right drug for the right patient at the right dose". But how
do these advantages play against a multitude of factors that could easily thwart
the progress of pharmacogenomics - ethics, intellectual property, an overburdened
healthcare system, and uncertain economic models of pricing and segmented markets?
In CHI's latest Summit Report, leading industry experts discuss strategies that
can help your company make use of genetic variation data toward gaining a competitive
edge in research, development and marketing.
Key issues discussed include:
- Impact of pharmacogenomics on the various stages of drug development
- Near and long term strategies and how they relate to the likely course of
pharmacogenomics adoption in the industry
- Research and development restructuring
- Third party genetic banking paving the way for research, diagnosis and medical
treatment
- Case study of a pharmacogenomics alliance
- Accessing global markets effectively through pharmacogenomic bridging trials
- How the genomics revolution will affect FDA regulation
- Sales and marketing implications of pharmacogenomics
- Results from financial models on the economic impact of pharmacogenomics
Report Format:
- 250+ pages of fully edited transcripts
- 120+ tables and figures
- 150+ weblinks
- Available as a company-wide document in print, PDF and HTML
About the Editor:
Mike Silver, Ph.D., Senior Analyst at Cambridge Healthtech Institute, received
his Ph.D. in Biochemistry and Molecular Biology from Harvard University and
his undergraduate degree in Chemistry from Columbia University. His former research
appointments included Brandeis, Columbia and Harvard Universities. Prior to
joining CHI, Dr. Silver held several senior editorial positions at NewsEdge
Corporation, Current Biology, Ltd., and co-founded an industry analysis and
publishing group at the Center for Business Intelligence.
List of Contributors:
Dr. Russ Altman of the Stanford Medical InformaticsGroup
Dr. Roy Bullingham, Vice President of Global Clinical Pharmacology at Pharmacia
Andrea Califano, Chief Technology Officer of First Genetic Trust
Dr. Tom Chu, Senior Scientist at Genset Corporation
Dr. Jeff Fairman, Senior Scientist at Clingenix, Inc
Craig Fitzgerald, Vice President of Commercial Genetics, Glaxo Wellcome
Dr. Joseph Hackett, Associate Director for Clinical Laboratory Devices at the
U.S. Food and Drug Administration
Dr. Michael Liebman, Global Head of Computational Genetics at Roche Bioscience
Dr. Trevor Nicholls, Chief Executive Officer of Oxagen Ltd
Ronald Norton, Director of Technical Services at PPGx Inc
Dr. Kal Ramnaryan, Chief Scientific Officer, Structural Bioinformatics
Allen D. Roses, Senior Vice President, Genetics Research, at GlaxoSmithKline.
Dr. Bonnie Gould Rothberg, Goup Leader Pharmacogenomics at Curagen Corporation
Dr. Thomas Rushmore of the Department of Drug Metabolism at Merck and Company.
Dr. William Wardell, Chief Scientific Officer at Covance Inc.
Dr. David Wiener, Principal Scientist at ACADIA PharmacoGenomics
View Cart
